Last update Dec. 9, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
A03BA04 is Belladona in ATC Code/s.Is written in other languages:
A03BA04 is also known as
A03BA04 belongs to these groups or families:
Main tradenames from several countries containing A03BA04 in its composition:
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
In herbal medicine the leaves of this plant that contains numerous alkaloids with anticholinergic and antimuscarinic properties are used: l-hyoscyamine and atropine, scopolamine or hyoscine and, all of them potentially high toxic. Traditionally used with poor clinical evidence based on trials as anti-asthmatic, for common colds and intestinal spasms.
At latest update no published data on excretion into breast milk were found.
Although antimuscarinics are thought to decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels.
Potential side effects are serious (tachycardia, thirst, fever, mydriasis, seizures, coma), especially in infants and newborns (Caksen 2003 Laffargue 2011, Glatstein 2014, Rodríguez-González 2014). There have been cases of gangrene when applied to the breast. (Wani 2011)
Belladonna is included in association with other “over the counter" medications of doubtful effectiveness or safety. Overall drug associations are not recommended. Withdrawal or restricted from the market in Spain. (MSC 2004)
Precautions when taking plant preparations: